Semaglutide Slows Epigenetic Aging Markers in HIV Trial, Study Finds

A clinical trial published in Nature Communications is drawing attention this week for a finding that was never actually the point of the original study: semaglutide, the GLP-1 receptor agonist sold as Ozempic and Wegovy, appears to slow the accumulation of DNA markers linked to biological aging.

<cite index="12-8">Published in Nature Communications, the study provides the first randomized, placebo-controlled evidence in humans that semaglutide may slow the buildup of DNA markers linked to biological aging in adults living with HIV.</cite> The lead authors, from UC San Diego and collaborating institutions, are Corley, Dwaraka, Pang, and colleagues, according to the paper as indexed in PubMed.

Here's what the data actually looked like. <cite index="13-3">The trial enrolled 45 adults with HIV-associated lipohypertrophy in the semaglutide arm and 39 in the placebo arm, over 32 weeks.</cite> <cite index="7-6">Researchers measured biological aging using epigenetic clocks, research tools that estimate how fast the body is aging based on chemical marks on DNA, a process called DNA methylation.</cite> <cite index="8-4">They found a 9% reduction in biological aging speed on the DunedinPACE epigenetic clock, alongside improvements in markers linked to mortality risk and age-related disease.</cite> <cite index="8-5">The improvements spanned aging-related measures associated with the blood, brain, heart, liver, kidneys, and metabolic health.</cite>

That's a wide list. Read the methods before you get excited.

<cite index="10-3,10-4">The parent trial's registered primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints. Epigenetic aging was not pre-specified.</cite> That's not a minor footnote. <cite index="16-7,16-8">Because the epigenetic aging analysis was post hoc and exploratory, it carries a higher risk of false-positive findings than a pre-specified primary outcome would.</cite> The authors say as much in the paper; this is a signal-generating result, not a confirmatory one.

The choice of population also matters for generalizability. <cite index="15-10">People living with HIV often show accelerated aging and persistent low-grade inflammation even with effective antiretroviral therapy, which elevates their risks for cardiovascular, hepatic, and neurocognitive complications.</cite> Whether the epigenetic-clock shifts seen here would replicate in people without HIV, who don't carry that baseline inflammatory burden, is simply unknown.

<cite index="13-1">GLP-1 receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging has been lacking.</cite> That's precisely why this paper is worth paying attention to even with its caveats. <cite index="11-6">Research has already linked GLP-1 medications to lower risks of cardiovascular disease, kidney disease, and some neurodegenerative disorders.</cite> An effect on aging biology, if it holds up, would add a mechanistic thread to what has so far been a list of correlative benefits.

<cite index="8-6">The study provides early clinical evidence that GLP-1 receptor agonists may influence biological pathways involved in aging and age-related diseases, but semaglutide is not proven to extend lifespan or reverse aging.</cite> No regulatory body has approved it for that purpose.

What's needed next is a prospective trial with epigenetic aging as a pre-registered primary endpoint, a broader population, and a longer follow-up window. <cite index="15-14">Further research is needed to test durability, clinical outcomes, and generalizability.</cite> The authors know this. The question is whether someone funds it before the hype cycle outruns the evidence, which, given the commercial stakes around GLP-1 drugs, is not a safe assumption.

Sources cited:
- Nature Communications (Corley et al., 2026) (https://www.nature.com/articles/s41467-026-72861-3)
- PubMed abstract (PMID 42156721) (https://pubmed.ncbi.nlm.nih.gov/42156721/)
- ScienceDaily, UC San Diego release, July 14 2026 (https://www.sciencedaily.com/releases/2026/07/260713084907.htm)
- Medical News Today, June 9 2026 (https://www.medicalnewstoday.com/articles/glp-1-drugs-ozempic-wegovy-may-slow-biological-aging)
- DistilInfo, July 16 2026 (https://distilinfo.com/2026/07/16/semaglutide-biological-aging-study/)